Suppr超能文献

活性氧和氮物种在肺动脉高压发展中的作用

Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension.

作者信息

Fulton David J R, Li Xueyi, Bordan Zsuzsanna, Haigh Stephen, Bentley Austin, Chen Feng, Barman Scott A

机构信息

Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.

Department of Forensic Medicine, Nanjing Medical University, Nanjing 211166, China.

出版信息

Antioxidants (Basel). 2017 Jul 6;6(3):54. doi: 10.3390/antiox6030054.

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vasculature that involves the loss of endothelial function together with inappropriate smooth muscle cell growth, inflammation, and fibrosis. These changes underlie a progressive remodeling of blood vessels that alters flow and increases pulmonary blood pressure. Elevated pressures in the pulmonary artery imparts a chronic stress on the right ventricle which undergoes compensatory hypertrophy but eventually fails. How PAH develops remains incompletely understood and evidence for the altered production of reactive oxygen and nitrogen species (ROS, RNS respectively) in the pulmonary circulation has been well documented. There are many different types of ROS and RNS, multiple sources, and collective actions and interactions. This review summarizes past and current knowledge of the sources of ROS and RNS and how they may contribute to the loss of endothelial function and changes in smooth muscle proliferation in the pulmonary circulation.

摘要

肺动脉高压(PAH)是一种肺部血管的进行性疾病,涉及内皮功能丧失以及平滑肌细胞异常生长、炎症和纤维化。这些变化是血管进行性重塑的基础,会改变血流并升高肺动脉血压。肺动脉压力升高会给右心室带来慢性压力,右心室会发生代偿性肥大,但最终会衰竭。PAH的发病机制仍未完全明确,肺循环中活性氧和活性氮(分别为ROS和RNS)生成改变的证据已得到充分证实。ROS和RNS有许多不同类型、多种来源以及共同作用和相互作用。本综述总结了关于ROS和RNS来源的过去和当前知识,以及它们如何导致肺循环中内皮功能丧失和平滑肌增殖变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/5618082/4e6913a16044/antioxidants-06-00054-g001.jpg

相似文献

1
Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension.
Antioxidants (Basel). 2017 Jul 6;6(3):54. doi: 10.3390/antiox6030054.
2
Reactive oxygen and nitrogen species in pulmonary hypertension.
Free Radic Biol Med. 2012 May 1;52(9):1970-86. doi: 10.1016/j.freeradbiomed.2012.02.041. Epub 2012 Mar 6.
3
Regulation of Smooth Muscle Cell Proliferation by NADPH Oxidases in Pulmonary Hypertension.
Antioxidants (Basel). 2019 Mar 5;8(3):56. doi: 10.3390/antiox8030056.
4
Deficiency of NOX1/nicotinamide adenine dinucleotide phosphate, reduced form oxidase leads to pulmonary vascular remodeling.
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):110-9. doi: 10.1161/ATVBAHA.113.302107. Epub 2013 Nov 14.
5
Contribution of oxidative stress to pulmonary arterial hypertension.
World J Cardiol. 2010 Oct 26;2(10):316-24. doi: 10.4330/wjc.v2.i10.316.
6
The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Lung Architecture Remodeling.
Antioxidants (Basel). 2017 Dec 19;6(4):104. doi: 10.3390/antiox6040104.
7
Reactive oxygen species in pulmonary vascular remodeling.
Compr Physiol. 2013 Jul;3(3):1011-34. doi: 10.1002/cphy.c120024.
8
Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.
Antioxid Redox Signal. 2019 Nov 10;31(14):1053-1069. doi: 10.1089/ars.2019.7753. Epub 2019 Mar 29.
9
Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases.
Basic Clin Pharmacol Toxicol. 2012 Jan;110(1):87-94. doi: 10.1111/j.1742-7843.2011.00785.x. Epub 2011 Sep 28.

引用本文的文献

1
Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
Antioxidants (Basel). 2025 Mar 21;14(4):377. doi: 10.3390/antiox14040377.
2
Pulmonary Hypertension and Hyperglycemia-Not a Sweet Combination.
Diagnostics (Basel). 2024 May 28;14(11):1119. doi: 10.3390/diagnostics14111119.
5
Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease.
J Transl Med. 2023 Aug 2;21(1):519. doi: 10.1186/s12967-023-04361-7.
6
Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension.
Antioxidants (Basel). 2023 Apr 26;12(5):1006. doi: 10.3390/antiox12051006.
9
The Impact of Tobacco Cigarettes, Vaping Products and Tobacco Heating Products on Oxidative Stress.
Antioxidants (Basel). 2022 Sep 16;11(9):1829. doi: 10.3390/antiox11091829.

本文引用的文献

1
Organizers and activators: Cytosolic Nox proteins impacting on vascular function.
Free Radic Biol Med. 2017 Aug;109:22-32. doi: 10.1016/j.freeradbiomed.2017.03.017. Epub 2017 Mar 21.
2
Role for Functional SOD2 Polymorphism in Pulmonary Arterial Hypertension in a Chinese Population.
Int J Environ Res Public Health. 2017 Mar 6;14(3):266. doi: 10.3390/ijerph14030266.
3
Hypoxia inhibits expression and function of mitochondrial thioredoxin 2 to promote pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol. 2017 May 1;312(5):L599-L608. doi: 10.1152/ajplung.00258.2016. Epub 2017 Jan 27.
4
Pleiotropic Effects of Statins on the Cardiovascular System.
Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537.
5
Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials.
PLoS One. 2016 Dec 19;11(12):e0168101. doi: 10.1371/journal.pone.0168101. eCollection 2016.
6
NADPH oxidase 4 is not involved in hypoxia-induced pulmonary hypertension.
Pulm Circ. 2016 Sep;6(3):397-400. doi: 10.1086/687756.
7
Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine.
Chest. 2017 Jan;151(1):181-192. doi: 10.1016/j.chest.2016.09.001. Epub 2016 Sep 16.
8
Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension.
Oncotarget. 2016 Aug 23;7(34):54263-54273. doi: 10.18632/oncotarget.10855.
10
Mitochondrial ROS Produced via Reverse Electron Transport Extend Animal Lifespan.
Cell Metab. 2016 Apr 12;23(4):725-34. doi: 10.1016/j.cmet.2016.03.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验